Gabriel Ghiaur

22PUBLICATIONS
96CO-AUTHORS
Molecular targetsHaematological tumoursHaematologyGene and molecular therapyMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|May 20, 2026
A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

|Feb 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

John Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur

|Nov 13, 2025
FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML.

Maria-Camelia Stancioaica, Daniel Coriu, Gabriel Ghiaur

|Aug 13, 2025
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies.

David Kegyes, Andrei Tat, Alin Stefan Vizitiu

|Jul 15, 2025
Differentiation, ageing and leukaemia alter the metabolic profile of human bone marrow haematopoietic stem and progenitor cells.

Maria-Eleni Lalioti, Mari Carmen Romero-Mulero, Noémie Karabacz

|Jun 04, 2025
Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML.

Ilias Sinanidis, Panagiotis Tsakiroglou, Benjamin Dubner

Pageof 4

Frequent Collaborators

4 joint publications

Ciprian Tomuleasa

3 joint publications

W Brian Dalton

2 joint publications

Suman Paul

2 joint publications

Mark J Levis